Flatiron Health
Each of these is a live brief written from what Flatiron Health shares in public: a problem you can work through, with teammates who respond to your decisions and no answer key.
Flatiron Health is an oncology-focused health-technology company and an independent Roche Group affiliate, providing point-of-care software for community oncology practices and cancer centers, and real-world data, analytics, and research services for life-sciences companies and clinical research teams. It sells OncoEMR to community oncology practices and connects care-delivery workflows with evidence generation across the oncology drug-development lifecycle. It has active partnerships with the top 25 oncology biopharma companies, many biotechs, top-tier academic medical centers, the FDA, NICE and other key stakeholders across the oncology care ecosystem. It partners with cancer hospitals and medical institutions in the US, Europe and Asia and creates real-world evidence from electronic health record patient data after removing personally identifying details. It advances the use of machine learning and generative AI to extract clinically relevant information from unstructured medical notes for oncology research. A remote abstraction workforce, primarily nurses, tumor registrars, and clinical research professionals, converts unstructured clinical data into structured, usable data.
Your first one is free. No card.
3 live right now.
The rest
Decide whether to pause ordering while genomic results lack context
Community oncologists cannot always link a genomic result to the treatment plan in front of them. You must decide whether continuity for active orders outweighs pausing the workflow until the clinical review boundary is proven.
Shorten order corrections while treatment plans stay reviewable
Infusion nurses are waiting while simple order corrections reopen completed plans. You must weigh a faster correction path against preserving the clinical review trail.